Apogee’s APG990 Phase 1 data show a 60-day half-life and strong tolerability, supporting long-interval dosing. A 2025 trial will compare APG279 to Dupixent.
Apogee Therapeutics’ Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial
